Similarly, synergism between TSA and another oncolytic HSV, the multi-attenuated HSV-1 mutant G47∆, was observed in animal models of GBM and colorectal cancer, with the enhanced anti-tumour activity being ascribed, at least in these cases, to cyclin D1 blockade and VEGF inhibition [73]. Here, VEGFA is linked to neoplasm.